169 related articles for article (PubMed ID: 38353868)
1. Pathological complete response of initially unresectable multiple liver metastases achieved using combined peptide receptor radionuclide therapy and somatostatin analogs following pancreatic neuroendocrine tumor resection: a case report.
Umino R; Nara S; Kobayashi N; Mizui T; Takamoto T; Ban D; Esaki M; Hiraoka N; Shimada K
Surg Case Rep; 2024 Feb; 10(1):40. PubMed ID: 38353868
[TBL] [Abstract][Full Text] [Related]
2. Surgical Feasibility, Determinants, and Overall Efficacy of Neoadjuvant
Parghane RV; Bhandare M; Chaudhari V; Ostwal V; Ramaswamy A; Talole S; Shrikhande SV; Basu S
J Nucl Med; 2021 Nov; 62(11):1558-1563. PubMed ID: 33637590
[TBL] [Abstract][Full Text] [Related]
3. The effect of long-acting somatostatin analogues on the uptake of [
Veerman CHAM; Siebinga H; de Vries-Huizing DMV; Tesselaar MET; Hendrikx JJMA; Stokkel MPM; Aalbersberg EA
Eur J Nucl Med Mol Imaging; 2023 Apr; 50(5):1434-1441. PubMed ID: 36598536
[TBL] [Abstract][Full Text] [Related]
4. Resection of the Primary Tumor Followed by Peptide Receptor Radionuclide Therapy as Upfront Strategy for the Treatment of G1-G2 Pancreatic Neuroendocrine Tumors with Unresectable Liver Metastases.
Bertani E; Fazio N; Radice D; Zardini C; Grana C; Bodei L; Funicelli L; Ferrari C; Spada F; Partelli S; Falconi M
Ann Surg Oncol; 2016 Dec; 23(Suppl 5):981-989. PubMed ID: 27613553
[TBL] [Abstract][Full Text] [Related]
5. Impressive Response to TANDEM Peptide Receptor Radionuclide Therapy with
Perrone E; Ghai K; Eismant A; Andreassen M; Langer SW; Knigge U; Kjaer A; Baum RP
Diagnostics (Basel); 2024 Apr; 14(9):. PubMed ID: 38732321
[TBL] [Abstract][Full Text] [Related]
6. Peptide receptor radionuclide therapy controls inappropriate calcitriol secretion in a pancreatic neuro-endocrine tumor: a case report.
Haemels M; Delaunoit T; Van Laere K; Van Cutsem E; Verslype C; Deroose CM
BMC Gastroenterol; 2020 Oct; 20(1):324. PubMed ID: 33008295
[TBL] [Abstract][Full Text] [Related]
7. Safety and Effectiveness of 177Lu-DOTATATE Peptide Receptor Radionuclide Therapy After Regional Hepatic Embolization in Patients With Somatostatin-Expressing Neuroendocrine Tumors.
Hamiditabar M; Ali M; Bolek L; Vahdati G; Tworowska I; Delpassand ES
Clin Nucl Med; 2017 Nov; 42(11):822-828. PubMed ID: 28832377
[TBL] [Abstract][Full Text] [Related]
8. Metastatic Neuroendocrine Tumor with Extensive Bone Marrow Involvement at Diagnosis: Evaluation of Response and Hematological Toxicity Profile of PRRT with (177)Lu-DOTATATE.
Basu S; Ranade R; Thapa P
World J Nucl Med; 2016; 15(1):38-43. PubMed ID: 26912977
[TBL] [Abstract][Full Text] [Related]
9. The prognostic influence of the proliferative discordance in metastatic pancreatic neuroendocrine carcinoma revealed by peptide receptor radionuclide therapy: Case report and review of literature.
Montanier N; Joubert-Zakeyh J; Pétorin C; Montoriol PF; Maqdasy S; Kelly A
Medicine (Baltimore); 2017 Feb; 96(6):e6062. PubMed ID: 28178157
[TBL] [Abstract][Full Text] [Related]
10. Pre-therapy Somatostatin Receptor-Based Heterogeneity Predicts Overall Survival in Pancreatic Neuroendocrine Tumor Patients Undergoing Peptide Receptor Radionuclide Therapy.
Werner RA; Ilhan H; Lehner S; Papp L; Zsótér N; Schatka I; Muegge DO; Javadi MS; Higuchi T; Buck AK; Bartenstein P; Bengel F; Essler M; Lapa C; Bundschuh RA
Mol Imaging Biol; 2019 Jun; 21(3):582-590. PubMed ID: 30014345
[TBL] [Abstract][Full Text] [Related]
11. Prevalence of hitherto unknown brain meningioma detected on
Parghane RV; Talole S; Basu S
World J Nucl Med; 2019; 18(2):160-170. PubMed ID: 31040748
[TBL] [Abstract][Full Text] [Related]
12. Is surgery indicated for patients with symptomatic nonfunctioning pancreatic neuroendocrine tumor and unresectable hepatic metastases?
Hung JS; Chang MC; Lee PH; Tien YW
World J Surg; 2007 Dec; 31(12):2392-7. PubMed ID: 17960455
[TBL] [Abstract][Full Text] [Related]
13. Tumor Contrast-Enhancement for Monitoring of PRRT
Pettersson O; Fröss-Baron K; Crona J; Sundin A
Front Oncol; 2020; 10():193. PubMed ID: 32154181
[No Abstract] [Full Text] [Related]
14. Surgery, Liver Directed Therapy and Peptide Receptor Radionuclide Therapy for Pancreatic Neuroendocrine Tumor Liver Metastases.
Ngongoni R; Visser B
Cancers (Basel); 2022 Oct; 14(20):. PubMed ID: 36291892
[TBL] [Abstract][Full Text] [Related]
15. Peptide receptor radionuclide therapy as a two-step strategy for initially unresectable liver disease from neuroendocrine tumors: a single-center experience.
Chiapponi C; Lürssen N; Cremer B; Wahba R; Drebber U; Faust M; Schmidt M; Stippel DL
Endocrine; 2020 Oct; 70(1):187-193. PubMed ID: 32419082
[TBL] [Abstract][Full Text] [Related]
16. Case report: Metastatic pancreatic neuroendocrine tumour associated with portal vein thrombosis; successful management with subsequent pregnancies.
Sira L; Zsíros N; Bidiga L; Barna S; Kanyári Z; Nagy EB; Guillaume N; Wild D; Rázsó K; Andó S; Balogh I; Nagy EV; Balogh Z
Front Endocrinol (Lausanne); 2023; 14():1095815. PubMed ID: 36923225
[TBL] [Abstract][Full Text] [Related]
17. In patients with well-differentiated neuroendocrine tumours, there is no apparent benefit of somatostatin analogues after disease control by peptide receptor radionuclide therapy.
Syguła A; Ledwon A; Hasse-Lazar K; Jurecka-Lubieniecka B; Michalik B; Paliczka-Cieślik E; Zeman M; Chmielik E; Sczasny J; Jarzab B; Handkiewicz-Junak D
Eur J Nucl Med Mol Imaging; 2022 Sep; 49(11):3841-3851. PubMed ID: 35503379
[TBL] [Abstract][Full Text] [Related]
18. Successful palliative peptide receptor radionuclide therapy for impending compression of vena cava due to unresectable liver metastasis of neuroendocrine tumor.
Ataeinia B; Loberg C; Kravets H; Beheshti M; von Mallek D; Mottaghy FM; Heinzel A
EXCLI J; 2019; 18():273-276. PubMed ID: 31338000
[TBL] [Abstract][Full Text] [Related]
19. Clinical Response Profile of Metastatic/Advanced Pulmonary Neuroendocrine Tumors to Peptide Receptor Radionuclide Therapy with 177Lu-DOTATATE.
Parghane RV; Talole S; Prabhash K; Basu S
Clin Nucl Med; 2017 Jun; 42(6):428-435. PubMed ID: 28319500
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and tolerability of peptide receptor radionuclide therapy (PRRT) in advanced metastatic bronchial neuroendocrine tumours (NETs).
Mirvis E; Toumpanakis C; Mandair D; Gnanasegaran G; Caplin M; Navalkissoor S
Lung Cancer; 2020 Dec; 150():70-75. PubMed ID: 33075738
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
